SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19
Brian J. Boyarsky(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Teresa Po‐Yu Chiang(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Julia I. López(Johns Hopkins Medicine), Aura T. Teles(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Michelle R. Krach(Johns Hopkins University), Iulia Barbur(Johns Hopkins University), Ross S. Greenberg(Johns Hopkins University), Michael T. Ou(Johns Hopkins University), Robin K. Avery(Johns Hopkins University)
Cited by 25
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
|JAMA|2021|536
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
|New England Journal of Medicine|2015|450